Teva’s asthma therapy Cinqaero receives NICE recommendation

Teva has announced that its asthma therapy Cinqaero has been recommended by the National Institute for Health and Care Excellence (NICE) for routine NHS use.

A final appraisal determination has been issued by the regulator recommending the humanised interleukin-5 antagonist monoclonal antibody as an add-on therapy for adult patients with severe eosinophilic asthma.

The drug is designed to benefit patients whose conditions have been inadequately controlled by high-dose inhaled corticosteroid therapy plus another medicinal product for maintenance treatment.

New monoclonal antibody treatments of this kind have demonstrated success in clinical trials, which have shown that drugs such as Cinqaero could be effective in treating around 30 to 40 percent of those living with severe asthma.

Sven Dethlefs, senior vice-president and head of global respiratory medicines at Teva, said: "The future of respiratory care shows great promise, and we are proud to be at the forefront of providing innovative medications for such a patient population whose quality of life is often severely impacted by asthma."

The drug has been available for sale in Europe since it was approved by the European Commission in August 2016.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.